| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
Non-cleavable Linker
The primary targets of N3-Ph-NHS ester are the linker structures in ADC technology. As a non-cleavable ADC linker, it connects the antibody to the cytotoxic payload through NHS ester-amine conjugation and aryl azide photoactivation. The compound is a click chemistry reagent, containing an azide moiety that can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules. It does not directly bind to enzymes or receptors but serves as a structural component. |
|---|---|
| ln Vitro |
In vitro, N3-Ph-NHS ester functions as a structural linker for ADC synthesis. The NHS ester group reacts with primary amines on antibodies, while the azide group can be used for further conjugation via click chemistry. This heterobifunctional nature allows for the creation of stable ADCs with defined conjugation sites. The compound itself does not exhibit direct cellular activity but enables the bioactivity of the conjugated therapeutic agent.
|
| ln Vivo |
In vivo activity of N3-Ph-NHS ester is realized through the ADC constructs in which it is incorporated. As a non-cleavable linker, it provides stability to the ADC in circulation, ensuring the cytotoxic payload remains attached until target cell engagement. The linker's stability and lack of degradation contribute to the overall efficacy of the ADC. The in vivo efficacy depends on the specific antibody and payload used in the conjugate.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for N3-Ph-NHS ester focus on evaluating the stability and reactivity of the linker. The compound is tested for its ability to conjugate to antibodies via NHS ester-amine reaction and to undergo click chemistry with alkyne-containing molecules. The conjugation efficiency is monitored by HPLC or mass spectrometry. The stability of the linker under physiological conditions is also assessed by incubating in buffer solutions at 37°C.
|
| Cell Assay |
In vitro cellular assays for N3-Ph-NHS ester involve testing the complete ADC molecule rather than the linker alone. Cancer cell lines are treated with the ADC, and cell viability is assessed using CCK-8 or MTT assays after 72 hours. The linker's contribution to ADC stability and activity is evaluated by comparing the activity of the ADC with that of the unconjugated payload. The linker itself does not directly affect cell viability.
|
| Animal Protocol |
In vivo animal studies for N3-Ph-NHS ester are conducted using the final ADC construct. Tumor-bearing xenograft models receive the ADC via intravenous injection. Tumor volume and body weight are monitored over 2-4 weeks to assess efficacy and tolerability. The linker contributes to the stability and PK profile of the ADC. Detailed in vivo protocols are similar to those used for other ADC linkers.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of N3-Ph-NHS ester are determined by the ADC in which it is incorporated. The compound has a molecular weight of approximately 247-252 and a molecular formula of C₁₁H₈N₄O₄. It is a non-cleavable linker, providing stability to the ADC in circulation. The linker's stability contributes to a favorable PK profile for the ADC, with prolonged half-life and reduced off-target toxicity.
|
| Toxicity/Toxicokinetics |
The toxicity profile of N3-Ph-NHS ester is associated with the ADC in which it is used. As a linker compound, it is considered to have low intrinsic toxicity. Standard toxicity studies for the final ADC include assessment of body weight changes, clinical observations, hematological parameters, and histopathological examination of major organs in animal models. The linker itself does not exhibit significant cytotoxic effects.
|
| Additional Infomation |
N3-Ph-NHS ester (CAS 53053-08-0) has a molecular formula of C₁₁H₈N₄O₄ and a molecular weight of approximately 247-252. It is a non-cleavable, heterobifunctional crosslinker featuring an amine-reactive NHS ester group and a photoactivatable aryl azide group connected by a short, rigid benzoate linker. It is used in the synthesis of ADCs and is a click chemistry reagent containing an azide group. The compound is intended for research use only and is not approved for clinical use.
|
| Molecular Formula |
C11H8N4O4
|
|---|---|
| Molecular Weight |
260.21
|
| Exact Mass |
260.055
|
| CAS # |
53053-08-0
|
| PubChem CID |
122153
|
| Appearance |
Off-white to yellow solid powder
|
| Melting Point |
171-172ºC
|
| LogP |
1.239
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
19
|
| Complexity |
434
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=C(C=CC(=C1)N=[N+]=[N-])C(=O)ON2C(=O)CCC2=O
|
| InChi Key |
LWAVGNJLLQSNNN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H8N4O4/c12-14-13-8-3-1-7(2-4-8)11(18)19-15-9(16)5-6-10(15)17/h1-4H,5-6H2
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 4-azidobenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 31.25 mg/mL (120.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.99 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.99 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (7.99 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8430 mL | 19.2152 mL | 38.4305 mL | |
| 5 mM | 0.7686 mL | 3.8430 mL | 7.6861 mL | |
| 10 mM | 0.3843 mL | 1.9215 mL | 3.8430 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
